Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Terminated 7Completed 5Withdrawn 1Active not recruiting 1

Sponsor Class

NIH 2INDUSTRY 2OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 86Carcinoma, Renal Cell 29Lymphoma 26Kidney Neoplasms 26Leukemia 25Leukemia, Myeloid, Acute 24Lymphoma, Follicular 16Lymphoma, Non-Hodgkin 15Lymphoma, Mantle-Cell 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Leukemia, Lymphocytic, Chronic, B-Cell 13Breast Neoplasms 12Neoplasm Metastasis 11Lymphoma, Large B-Cell, Diffuse 10Lymphoma, B-Cell, Marginal Zone 10Skin Neoplasms 9Myelodysplastic Syndromes 9Lymphoma, Large-Cell, Immunoblastic 9Hodgkin Disease 9Burkitt Lymphoma 9Neuroblastoma 8Congenital Abnormalities 8Recurrence 7Ovarian Neoplasms 7Multiple Myeloma 7Carcinoma, Non-Small-Cell Lung 7Pancreatic Neoplasms 6Leukemia, Myelomonocytic, Chronic 6Gliosarcoma 6Glioblastoma 6

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Neoplasms × aldesleukin × Clear all
NCT02876510 2025-02-04

ACTolog

Immatics US, Inc.

Phase 1 Completed
38 enrolled
GastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT03296137 2024-10-26

Adoptive Cell Therapy Across Cancer Diagnoses

Herlev Hospital

Phase 1/2 Completed
25 enrolled 9 charts
Tumor-Agnostic

Neoplasms

NCT00513604 2013-06-03

Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
158 enrolled 14 charts
Dermatologic

Melanoma, Melanoma, Experimental, Neoplasms, Skin Neoplasms

NCT00329368 2012-03-09

Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer

Endocyte

Phase 1 Completed
13 enrolled

Neoplasms, Recurrence

NCT00393029 2011-08-15

Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
12 enrolled 10 charts
Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡